Sistema de Gestión del Conocimiento ANLIS MALBRÁN
Not a member yet
3661 research outputs found
Sort by
Bedaquiline and linezolid MIC distributions and epidemiological cut-off values for Mycobacterium tuberculosis in the Latin American region
No full textFil: López, Beatriz. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriologia; Argentina.Fil: Siqueira de Oliveira, Rosangela. Instituto Adolfo Lutz Sao Paulo. Centro de Bacteriología. Nucleo de Tuberculose e Micobacterioses; Brasil.Fil: Pinhata, Juliana M. W. Instituto Adolfo Lutz Sao Paulo. Centro de Bacteriología. Nucleo de Tuberculose e Micobacterioses; Brasil.Fil: Chimara, Erica. Instituto Adolfo Lutz Sao Paulo. Centro de Bacteriología. Nucleo de Tuberculose e Micobacterioses; Brasil.Fil: Pacheco Ascencio, Edson. Instituto Nacional de Salud. Laboratorio de Referencia Nacional de Micobacterias; Lima, Perú.Fil: Puyén Guerra, Zully M. Instituto Nacional de Salud. Laboratorio de Referencia Nacional de Micobacterias; Lima, Perú.Fil: Wainmayer, Ingrid. ANLIS Dr.C.G.Malbrán. Insituto Nacional de Enfermededades Infecciosas. Servicio de Micobacterias; Argentina.Fil: Simboli, Norberto. ANLIS Dr.C.G.Malbrán. Insituto Nacional de Enfermededades Infecciosas. Servicio de Micobacterias; Argentina.Fil: Del Granado, Mirtha. Pan American Health Organization; Estados Unidos.Fil: Palomino, Juan Carlos. Ghent University. Department of Biochemistry and Microbiology. Faculty of sciences; Belgica.Fil: Ritacco, Viviana. ANLIS Dr.C.G.Malbrán. Insituto Nacional de Enfermededades Infecciosas. Servicio de Micobacterias; Argentina.Fil: Martín, Anandi. Université catholique de Louvain. Institute of Experimental and Clinical Research. Laboratory of Medical Microbiology; Belgica.Objectives: To describe the distributions of bedaquiline and linezolid MIC values for the Mycobacterium tuberculosis WT population and to define the corresponding epidemiological cut-offs (ECOFFs) in three Latin American countries.
Methods: MICs of bedaquiline and linezolid were determined by the resazurin microtitre assay (REMA). In phase 1, interlaboratory reproducibility was assessed using a panel of 10 fully susceptible M. tuberculosis strains. Phase 2 involved MIC determination for 248 clinical isolates from Argentina (n = 58), Brazil (n = 100) and Peru (n = 90) from patients who were treatment-naive for bedaquiline and linezolid. We then determined the ECOFFs for bedaquiline and linezolid by the eyeball method and the ECOFFinder statistical calculator.
Results: Phase 1: REMA MIC values in the three sites were either identical to each other or differed by one 2-fold dilution from the consensus value with the exception of a single value. Phase 2: the bedaquiline MIC range was 0.0039-0.25 mg/L for pan-susceptible and drug-resistant isolates combined. The linezolid MIC range was 0.062-0.5 mg/L for pan-susceptible isolates and 0.031-4 mg/L for drug-resistant isolates. ECOFFs were 0.125 mg/L for bedaquiline and 0.50 mg/L for linezolid.
Conclusions: REMA is reproducible and robust for the determination of bedaquiline and linezolid MIC distributions and ECOFF values when applied in laboratories of medium/low-resource countries. We suggest that WT MIC distributions for both drugs should be used as a monitoring tool to control the possible rapid emergence of resistance
Resistance to β-lactams in enterococci
No full textFil: Gagetti, Paula. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriología. Servicio Antimicrobianos; Argentina.Fil: Bonofiglio, Laura. Grupo STREP de la Sociedad Argentina de Bacteriología, Micología y Parasitología Clínicas (SADEBAC), División de la Asociación Argentina de Microbiología, Argentina; Cátedra de Microbiología, Facultad de Farmacia y Bioquímica, Departamento de Microbiología, Inmunología y Biotecnología, Universidad de Buenos Aires; Argentina.Fil: García Gabarrot, Gabriela. Grupo STREP de la Sociedad Argentina de Bacteriología, Micología y Parasitología Clínicas (SADEBAC), División de la Asociación Argentina de Microbiología, Argentina; Programa de Desarrollo de las Ciencias Básicas (PEDECIBA), Universidad de la República; Uruguay.Fil: Kaufman, Sara. Grupo STREP de la Sociedad Argentina de Bacteriología, Micología y Parasitología Clínicas (SADEBAC), División de la Asociación Argentina de Microbiología, Argentina; Sección Microbiología Clínica, División Laboratorio, Hospital Juan A. Fernández; Argentina.Fil: Mollerach, Marta. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriología. Servicio Antimicrobianos; Argentina.Fil: Vigliarolo, Laura. Grupo STREP de la Sociedad Argentina de Bacteriología, Micología y Parasitología Clínicas (SADEBAC), División de la Asociación Argentina de Microbiología, Argentina; Cátedra de Microbiología Clínica, Facultad de Ciencias Exactas, Universidad Nacional de La Plata; Argentina.Fil: von Specht, Martha H. Grupo STREP de la Sociedad Argentina de Bacteriología, Micología y Parasitología Clínicas (SADEBAC), División de la Asociación Argentina de Microbiología, Argentina; Laboratorio de Bacteriología, Hospital "Dr Fernando Barreyro"; Argentina.Fil: Toresani, Inés. Grupo STREP de la Sociedad Argentina de Bacteriología, Micología y Parasitología Clínicas (SADEBAC), División de la Asociación Argentina de Microbiología; Argentina.Fil: Lopardo, Horacio A. Grupo STREP de la Sociedad Argentina de Bacteriología, Micología y Parasitología Clínicas (SADEBAC), División de la Asociación Argentina de Microbiología, Argentina; Cátedra de Microbiología Clínica, Facultad de Ciencias Exactas, Universidad Nacional de La Plata; Argentina.Enterococci are intrinsically resistant to several antimicrobial classes and show a great ability to acquire new mechanisms of resistance. Resistance to β-lactam antibiotics is a major concern because these drugs either alone or in combination are commonly used for the treatment of enterococcal infections. Ampicillin resistance, which is rare in Enterococcus faecalis, occurs in most of the hospital-associated Enterococcus faecium isolates. High-level resistance to ampicillin in E. faecium is mainly due to the enhanced production of PBP5 and/or by polymorphisms in the beta subunit of this protein. The dissemination of high-level ampicillin resistance can be the result of both clonal spread of strains with mutated pbp5 genes and horizontal gene transfer
Klebsiella pneumoniae ST258 Negatively Regulates the Oxidative Burst in Human Neutrophils
No full textFil: Castillo, Luis A. Consejo Nacional de investigaciones Científicas y Tecnológicas (CONICET). Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental (IMEX). Laboratorio de Fisiología de los Procesos Inflamatorios; Argentina.Fil: Birnberg-Weiss, Federico. Consejo Nacional de investigaciones Científicas y Tecnológicas (CONICET). Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental (IMEX). Laboratorio de Fisiología de los Procesos Inflamatorios; Argentina.Fil: Rodriguez-Rodrigues, Nahuel. Consejo Nacional de investigaciones Científicas y Tecnológicas (CONICET). Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental (IMEX). Laboratorio de Fisiología de los Procesos Inflamatorios; Argentina.Fil: Martire-Greco, Daiana. Consejo Nacional de investigaciones Científicas y Tecnológicas (CONICET). Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental (IMEX). Laboratorio de Fisiología de los Procesos Inflamatorios; Argentina.Fil: Bigi, Fabiana. Consejo Nacional de investigaciones Científicas y Tecnológicas (CONICET). Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular (IABIMO); Argentina.Fil: Landoni, Veronica I. Consejo Nacional de investigaciones Científicas y Tecnológicas (CONICET). Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental (IMEX). Laboratorio de Fisiología de los Procesos Inflamatorios; Argentina.Fil: Gomez, Sonia A. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriología. Servicio Antimicrobianos; Argentina.Fil: Fernandez, Gabriela C. Consejo Nacional de investigaciones Científicas y Tecnológicas (CONICET). Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental (IMEX). Laboratorio de Fisiología de los Procesos Inflamatorios; Argentina.The epidemic clone of Klebsiella pneumoniae (Kpn), sequence type 258 (ST258), carbapenamase producer (KPC), commonly infects hospitalized patients that are left with scarce therapeutic option since carbapenems are last resort antibiotics for life-threatening bacterial infections. To improve prevention and treatment, we should better understand the biology of Kpn KPC ST258 infections. Our hypothesis was that Kpn KPC ST258 evade the first line of defense of innate immunity, the polymorphonuclear neutrophil (PMN), by decreasing its functional response. Therefore, our aim was to evaluate how the ST258 Kpn clone affects PMN responses, focusing on the respiratory burst, compared to another opportunistic pathogen, Escherichia coli (Eco). We found that Kpn KPC ST258 was unable to trigger bactericidal responses as reactive oxygen species (ROS) generation and NETosis, compared to the high induction observed with Eco, but both bacterial strains were similarly phagocytized and cause increases in cell size and CD11b expression. The absence of ROS induction was also observed with other Kpn ST258 strains negative for KPC. These results reflect certain selectivity in terms of the functions that are triggered in PMN by Kpn, which seems to evade specifically those responses critical for bacterial survival. In this sense, bactericidal mechanisms evasion was associated with a higher survival of Kpn KPC ST258 compared to Eco. To investigate the mechanisms and molecules involved in ROS inhibition, we used bacterial extracts (BE) and found that BE were able to inhibit ROS generation triggered by the well-known ROS inducer, fMLP. A sequence of experiments led us to elucidate that the polysaccharide part of LPS was responsible for this inhibition, whereas lipid A mediated the other responses that were not affected by bacteria, such as cell size increase and CD11b up-regulation. In conclusion, we unraveled a mechanism of immune evasion of Kpn KPC ST258, which may contribute to design more effective strategies for the treatment of these multi-resistant bacterial infections
First case report of cryptococcosis due to Cryptococcus decagattii in a pediatric patient in Argentina
No full textFil: Berejnoi, Ana. Hospital Público Materno Infantil; Argentina.Fil: Taverna, Constanza Giselle. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.Fil: Mazza, Mariana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.Fil: Vivot, Matías. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.Fil: Isla, Guillermina. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.Fil: Córdoba, Susana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.Fil: Davel, Graciela. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.We report the first case of cryptococcosis due to Cryptococcus decagattii in an immunocompetent pediatric patient from an indigenous community in Argentina with a successful outcome. Two isolates (blood, cerebrospinal fluid) were genotyped by restriction fragment length polymorphism of the orotidine monophosphate pyrophosphorylase (URA5) gene as VGIV and identified by multi-locus sequence typing as C. decagattii. Matrix-assisted laser desorption/ionization time of flight mass spectrometry identification indicated genotype VGIII. The minimum inhibitory concentration of amphotericin B, fluconazole, itraconazole, and voriconazole was determined (cerebrospinal fluid: 0.25, 16, 0.12, and 0.12, blood: 0.25, 4, 0.12, and 0.06, respectively, all in mg/L)
Reportable mycoses: Utopia or reality. A forgotten matter still unresolved
No full textFil: Fernández, Norma. Editora de la Revista Argentina de Microbiología; ArgentinaFil: Davel, Graciela Odelsia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.A pesar de que los patógenos fúngicos representan una importante amenaza para la salud humana y animal, es una realidad innegable que la vigilancia epidemiológica de las micosis o enfermedades fúngicas todavía no es considerada una cuestión prioritaria en el sistema de salud nacional e internacional.
Respecto de la dimensión de este problema, se estima que el impacto de las enfermedades fúngicas en 14 países que reportaron este tipo de enfermedades (representando al 12,5% de la población global) es de alrededor del 2% 3
Pilot field trial of the EG95 vaccine against ovine cystic echinococcosis in Rio Negro, Argentina: 8 years of work
No full textFil: Larrieu, Edmundo. Universidad Nacional de La Pampa. Facultad de Ciencias Veterinarias; Argentina.Fil: Mujica, Guillermo. Ministerio de Salud, Provincia de Río Negro; Argentina.Fil: Araya, Daniel. Ministerio de Salud, Provincia de Río Negro; Argentina.Fil: Labanchi, Jose Luis. Ministerio de Salud, Provincia de Río Negro; Argentina.Fil: Arezo, Marcos. Ministerio de Salud, Provincia de Río Negro; Argentina.Fil: Herrero, Eduardo. Ministerio de Salud, Provincia de Río Negro; Argentina.Fil: Santillán, Graciela. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Parasitología; Argentina.Fil: Vizcaychipi, Katherina A. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Parasitología; Argentina.Fil: Uchiumi, Leonardo. Ministerio de Salud, Provincia de Río Negro; Argentina.Fil: Salvitti, Juan Carlos. Ministerio de Salud, Provincia de Río Negro; Argentina.Fil: Grizmado, Claudia. Ministerio de Salud, Provincia de Río Negro; Argentina.Fil: Calabro, Arnoldo. Ministerio de Salud, Provincia de Río Negro; Argentina.Fil: Talmon, Gabriel. Ministerio de Salud, Provincia de Río Negro; Argentina.Fil: Sepulveda, Luis. Ministerio de Salud, Provincia de Río Negro; Argentina.Fil: Galvan, Jose María. Ministerio de Salud, Provincia de Río Negro; Argentina.Fil: Cabrera, Marta. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Parasitología; Argentina.Fil: Seleiman, Marcos. Ministerio de Salud, Provincia de Río Negro; Argentina.Fil: Crowley, Pablo. Universidad Nacional de Río Negro. Escuela de Veterinaria; Argentina.Fil: Cespedes, Graciela. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Parasitología; Argentina.Fil: García Cachau, Mariela. Universidad Nacional de La Pampa. Facultad de Ciencias Veterinarias; Argentina.Fil: Gino, Lilia. Universidad Nacional de La Pampa. Facultad de Ciencias Veterinarias; Argentina.Fil: Molina, Leonardo. Universidad Nacional de La Pampa. Facultad de Ciencias Veterinarias; Argentina.Fil: Daffner, Jose. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Parasitología; Argentina.Fil: Gauci, Charles G. University of Melbourne. Faculty of Veterinary and Agricultural Sciences; Australia.Fil: Donadeu, Meritxell. University of Melbourne. Faculty of Veterinary and Agricultural Sciences; Australia.Fil: Lightowlers, Marshall W. University of Melbourne. Faculty of Veterinary and Agricultural Sciences; Australia.Cystic echinococcosis (CE) is endemic in the Rio Negro province of Argentina. After 30 years of control using praziquantel in dogs the transmission rate to humans and sheep has decreased significantly, however transmission persists. The objective of the study was to assess the inclusion of the EG95 for sheep in the control program and to determine the vaccine's operative feasibility in field conditions. An intervention study was defined in Rio Negro Province in Argentina comprising, in total, an area of 5820 Km2. Lambs received two vaccinations with the EG95 vaccine followed by a single booster injection when the animals were 1-1.5 years of age. Vaccination of lambs born into one trial site was introduced and continued for 8 years. Evidence for Echinococcus granulosus transmission was monitored before and after vaccination by coproantigen ELISA in faecal samples of dog, purgation of dogs to detect E. granulosus worms, necropsy on adult sheep and by ultrasound screening in children of 6-14 years old. 29,323 doses of vaccine were applied between 2009 and 2017, which a vaccination coverage of 80.1%/85.7% (57.3% average for fully vaccinated). Before the introduction of the vaccine 56.3% of the 6-year-old sheep were infected with E. granulosus at necropsy and 84.2% of the farms had infected sheep; 4.3% of the dogs were positive for E. granulosus infection using the arecoline test, and with coproELISA 9.6% of dog fecal samples were positive and 20.3% of the farms had infected dog.After the vaccine was introduced, 21.6% of sheep older than 6 years were found to be infected at necropsy and 20.2% of the farms were found to be infected; in dogs, 4.5% were found positive for E. granulosus using arecoline purgation and with coproELISA 3.7% of samples were positive, with 8.9% of farms having a positive dog. In 2016 only one case of E. granulosus infection was diagnosed by US screening in a 6-14 years old child. Included in the analysis are discussions of difficulties experienced in the field which affected correct vaccine administration as well as social features and practices that may impact on echinococcosis control and the EG95 vaccination program in Rio Negro. Vaccination of sheep with the EG95 vaccine provides a valuable new tool which improves the effectiveness of CE control activities. Vaccination was effective even in a difficult, remote environment where only approximately half the lambs born into the communities were fully vaccinated
Vector competence of Aedes aegypti for different strains of Zika virus in Argentina
Get PDFFil: Bonica, Melisa Berenice. Centro de Estudios Parasitológicos y de Vectores (CEPAVE-CONICET), Universidad Nacional de La Plata, La Plata, Buenos Aires; Argentina.Fil: Goenaga, Silvina. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.Fil: Martin, María Laura. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.Fil: Feroci, Mariel. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.Fil: Luppo, Victoria. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.Fil: Muttis, Evangelina. Centro de Estudios Parasitológicos y de Vectores (CEPAVE-CONICET), Universidad Nacional de La Plata, La Plata, Buenos Aires; Argentina.Fil: Fabbri, Cintia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.Fil: Morales, María Alejandra. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.Fil: Enria, Delia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.Fil: Micieli, María Victoria. Centro de Estudios Parasitológicos y de Vectores (CEPAVE-CONICET), Universidad Nacional de La Plata, La Plata, Buenos Aires; Argentina.Fil: Levis, Silvana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.The importance of Zika virus (ZIKV) has increased noticeably since the outbreak in the Americas in 2015, when the illness was associated with congenital disorders. Although there is evidence of sexual transmission of the virus, the mosquito Aedes aegypti is believed to be the main vector for transmission to humans. This species of mosquito has not only been found naturally infected with ZIKV, but also has been the subject of study in many vector competence assays that employ different strains of ZIKV around the world. In Argentina, the first case was reported in February 2016 and a total of 278 autochthonous cases have since been confirmed, however, ZIKV virus has not been isolated from any mosquito species yet in Argentina. In order to elucidate if Argentinian Ae. aegypti populations could be a possible vector of ZIKV, we conducted vector competence studies that involved a local strain of ZIKV from Chaco province, and a Venezuelan strain obtained from an imported case. For this purpose, Ae. aegypti adults from the temperate area of Argentina (Buenos Aires province) were fed with infected blood. Body, legs and saliva were harvested and tested by plaque titration on plates of Vero cells for ZIKV at 7, 11 and 14 days post infection (DPI) in order to calculate infection, transmission, and dissemination rates, respectively. Both strains were able to infect mosquitoes at all DPIs, whereas dissemination and transmission were observed at all DPIs for the Argentinian strain but only at 14 DPI for the Venezuelan strain. This study proves the ability of Ae. aegypti mosquitoes from Argentina to become infected with two different strains of ZIKV, both belonging to the Asian lineage, and that the virus can disseminate to the legs and salivary glands
Reidentification and antifungal susceptibility profile of Candida guilliermondii and Candida famata clinical isolates from a culture collection in Argentina
No full textFil: Taverna, Constanza Giselle. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.Fil: Córdoba, Susana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.Fil: Vivot, Matias Ezequiel. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.Fil: Szusz, Wanda. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.Fil: Vivot, Walter. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.Fil: Bosco-Borgeat, María Eugenia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.Fil: Davel, Graciela Odelsia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.The aim of this work was to reidentify strains previously identified as Candida guilliermondii and Candida famata by conventional phenotypic methods conserved in a culture collection from Argentina using ribosomal DNA sequencing, ACT1 gene sequencing, and matrix-assisted laser desorption ionization - time of flight mass spectrometry (MALDI-TOF MS). In addition, we performed antifungal susceptibility tests of eight antifungal drugs commonly used in clinical treatment. We identified 68 isolates belonging to the Candida guilliermondii species complex (59 C. guilliermondii, 8 C. fermentati, and 1 Candida carpophila), 16 isolates belonging to the Candida famata species complex (8 C. famata, 6 Debaryomyces nepalensis, 1 Debaryomyces fabryi, and 1 Debaryomyces tyrocola). Although sequencing of ITS region was able to identify C. guilliermondii and D. nepalensis isolates, sequencing of ACT1 gene seems to be the most appropriate technique for differentiation between C. fermentati and C. carpophila and between members of the C. famata species complex others than D. nepalensis. MALDI-TOF MS has a good potential for the identification of these yeasts, particularly in clinical laboratories since is a rapid and easy to perform technique. Here, we report the first isolation of D. tyrocola from a human patient and the first isolation of D. nepalensis from lungs and blood of human patients. Finally, correct identification and determination of antifungal susceptibility of those closely related species could be a useful tool for clinicians to choose the most effective antifungal treatment
Effects of Trypanocidal Treatment on Echocardiographic Parameters in Chagas Cardiomyopathy and Prognostic Value of Wall Motion Score Index: A BENEFIT Trial Echocardiographic Substudy
No full textSerial echocardiographic studies in chronic Chagas cardiomyopathy are scarce. The aims of this study were to evaluate whether therapy with benznidazole modifies the progression of cardiac impairment and to identify baseline echocardiographic parameters related to prognosis
Effects of Trypanocidal Treatment on Echocardiographic Parameters in Chagas Cardiomyopathy and Prognostic Value of Wall Motion Score Index: A BENEFIT Trial Echocardiographic Substudy
No full textSerial echocardiographic studies in chronic Chagas cardiomyopathy are scarce. The aims of this study were to evaluate whether therapy with benznidazole modifies the progression of cardiac impairment and to identify baseline echocardiographic parameters related to prognosis